Home Featured Page 2

Featured

Latest

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Martha Hammel and Tasia Poinsatte – Aspen Psychedelic Symposium

Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona

Erica Rex: Seeing What Is There, Trauma, Integration, and the Limits of Psychedelic Therapy

Inclius Alvarious’s Place Within Indigenous Society

Worth the Wait: Cambridge Adds Its Voice to UK Psychedelic Science

Q1 2026 Psychedelic Patent Update

The Psychedelic Practitioner Issue 4: Integration

Shane Mauss – Comedy and Molecules – Episode 14

March 2026 Psychedelic Bill Round-up

Ketamine-Assisted Couple Therapy Training by Enamory

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of...

The Psychedelic Writers Guild’s Denver Mixer

EDITOR PICKS

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive...

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics...

Martha Hammel and Tasia Poinsatte – Aspen Psychedelic Symposium

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Martha Hammel and Tasia Poinsatte – Aspen Psychedelic Symposium

Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona

Erica Rex: Seeing What Is There, Trauma, Integration, and the Limits of Psychedelic Therapy

Inclius Alvarious’s Place Within Indigenous Society

Worth the Wait: Cambridge Adds Its Voice to UK Psychedelic Science

Q1 2026 Psychedelic Patent Update

The Psychedelic Practitioner Issue 4: Integration

Shane Mauss – Comedy and Molecules – Episode 14

March 2026 Psychedelic Bill Round-up

Ketamine-Assisted Couple Therapy Training by Enamory

Quarterly Briefing: Q1 2026

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of...

The Psychedelic Writers Guild’s Denver Mixer

EDITOR PICKS

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive...

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics...

Martha Hammel and Tasia Poinsatte – Aspen Psychedelic Symposium

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY